I'm grateful to have Professor Shi Zheng Li as my supervisor, whose unwavering support and guidance have been instrumental in my growth as a scientist. Her kindness, expertise, and dedication exemplify the ideal mentorship that fosters excellence. Thank you, Professor Li
Ticks in Pakistan aren’t just biting — they’re carrying a viral universe.
31 viruses related sequences from 11 families. We found Jingmen tick virus + confirmed it’s actively infecting humans, livestock & rats. Zoonotic risk is real. Full paper 👇
https://t.co/XA6F8kJ1IP
Final call for applications! #ISID is seeking the next Editor-in-Chief of the International Journal of Infectious Diseases (IJID). Submissions close next week on April 20, 2026.
Learn more and apply now: https://t.co/X8yf2tlsic
#IJID#InfectiousDiseases#AcademicPublishing
Two months left to apply for our infectious disease clinical trial funding! ⏳
We’re looking to support clinical trials that generate real-world evidence to improve the treatment and prevention of infectious diseases. If your team can deliver actionable data to change national, regional or global health policies within 5–10 years, we want to hear from you.
To ensure this research addresses the priorities of the communities most affected, lead applicants must be based in Africa, South Asia, or South-East Asia.
• Level: £1mn - £8mn per award.
• Duration: 3 – 5 years
• Deadline: 2 June 2026
Delivered in partnership with @NIHRresearch.
Find out more and apply ⤵️
https://t.co/r4NSMiICJK
One Health lessons on arboviruses for stronger preparedness in LMICs
Join @who for this online session 31 March. Registration ⬇️
@WOAH@DrTedros@Chikwe_I
https://t.co/SuO2jmaLAs
#mBio & 3 other ASM journals announce an open call for volunteer editors. If you're a scientist committed to advancing top-tier microbiology & fair, rigorous peer review, join the mBio Board! Apply by April 24. Details on the process & qualifications at https://t.co/HRn7pB3RCN
#ISID is seeking the next Editor-in-Chief of the International Journal of Infectious Diseases! Help shape one of the leading journals advancing infectious disease research worldwide.
Learn more and apply:
https://t.co/MmsNRcOEsg
#IJID#InfectiousDiseases#AcademicPublishing
Just out: Epidemiology and genomic features of #MERS#coronavirus in #Africa: a systematic and meta-analysis #review - International Journal of Infectious Diseases https://t.co/fegQJRFrw7
Our Collaborative Project with Wuhan Institute Virology has been declared as one of the top 10 important events of 2025 in Wuhan Institute of Virology
@Anwar_Hashem@MarionKoopmans@SystemsVirology
📢 Applications are open for the Junior Scientist Program under the Germany– @CGIAR++ Science & Impact Hub.
Get hands-on experience, mentorship and work with partners turning research into real-world impact.
🗓 Deadline: 15 Feb 2026
Apply:🔗 https://t.co/CCuoSPPBoh
@giz_gmbh
🚀 Prof. Leo Poon (@world_epidemic)'s team (#HKUMed & #HKJCGHI) develops novel live-attenuated vaccine that blocks coronavirus transmission with a single intranasal dose. Published in @PNASNews 🔗
https://t.co/7z94pO5Wko
🚨 Postdoc/Project Position Alert @ IBAB Bengaluru!
Institute for Bioinformatics & Applied Biotechnology (IBAB) seeks Postdoc/Project Associates for DBT-funded projects
Details: https://t.co/pQCn50Ini6
#Postdoc#Bioinformatics#CompBio#AIinDrugDiscovery#BengaluruJobs
🎓📢 Call for Applications!
@AfricaCDC, in collaboration with @CEPIvaccines, invites applications for an 8-week online Data & Safety Monitoring Board (DSMB) Training Programme
🗓️ Starts: 12 Feb 2026
➡️ Application deadline: 31 January
🔗 https://t.co/WjknmP88dC
Our lab has an opening for a fully funded postdoc position! Start date is flexible; ideally summer 2026. Apply by Feb 20th for full consideration. For more about the lab and how to apply:
https://t.co/faMrVc2X75
Recruitment for the EMBL International PhD Programme is officially open!🔊
At EMBL, we train young scientists to become skilled and creative future leaders in academia, industry and other sectors. Start your career in the life sciences with us!
🔎 https://t.co/EYfcVvlHFT